FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981681176> ?p ?o ?g. }

• W2981681176 endingPage "1076" @default.
• W2981681176 startingPage "1061" @default.
• W2981681176 abstract "Background and Purpose Inhibition of the T‐ and B‐cell interaction through the CD40/CD40 ligand (L) axis is a favourable approach for inflammatory disease treatment. Clinical studies of anti‐CD40L molecules in autoimmune diseases have met challenges because of thromboembolic events and adverse haemostasis. VIB4920 (formerly MEDI4920) is a novel CD40L antagonist and Tn3 fusion protein designed to prevent adverse haemostasis and immunopharmacology. We evaluated the pharmacokinetics, activity and toxicity of VIB4920 in monkeys. Experimental Approach Cynomolgus monkeys received i.v. or s.c. 5–300 mg·kg −1 VIB4920 or vehicle, once weekly for 1 month (Studies 1 and 2) or 28 weeks (Study 3). VIB4920 exposure and bioavailability were determined using pharmacokinetic analyses, and immune cell population changes via flow cytometry. Pharmacological activity was evaluated by measuring the animals' capacity to elicit an immune response to keyhole limpet haemocyanin (KLH) and tetanus toxoid (TT). Key Results VIB4920 demonstrated linear pharmacokinetics at multiple doses. Lymphocyte, monocyte, cytotoxic T‐cell and NK cell counts were not significantly different between treatment groups. B‐cell counts reduced dose‐dependently and the T‐cell dependent antibody response to KLH was suppressed by VIB4920 dose‐dependently. The recall response to TT was similar across treatment groups. No thromboembolic events or symptoms of immune system dysfunctionality were observed. Conclusions and Implications VIB4920 demonstrated an acceptable safety profile in monkeys. VIB4920 showed favourable pharmacokinetics, dose‐dependent inhibition of a neoantigen‐specific immune response and no adverse effects on immune function following long‐term use. Our data support the use of VIB4920 in clinical trials." @default.
• W2981681176 created "2019-11-01" @default.
• W2981681176 creator A5011433734 @default.
• W2981681176 creator A5020442907 @default.
• W2981681176 creator A5021352966 @default.
• W2981681176 creator A5027193785 @default.
• W2981681176 creator A5038849475 @default.
• W2981681176 creator A5049056803 @default.
• W2981681176 creator A5051378395 @default.
• W2981681176 creator A5051881041 @default.
• W2981681176 creator A5060134825 @default.
• W2981681176 creator A5074196616 @default.
• W2981681176 creator A5087231670 @default.
• W2981681176 date "2020-02-03" @default.
• W2981681176 modified "2023-10-02" @default.
• W2981681176 title "The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys" @default.
• W2981681176 cites W1483584036 @default.
• W2981681176 cites W1518371662 @default.
• W2981681176 cites W1561516029 @default.
• W2981681176 cites W1593555249 @default.
• W2981681176 cites W1863725102 @default.
• W2981681176 cites W1914573154 @default.
• W2981681176 cites W1920961497 @default.
• W2981681176 cites W2003267341 @default.
• W2981681176 cites W2017390384 @default.
• W2981681176 cites W2029957805 @default.
• W2981681176 cites W2031626602 @default.
• W2981681176 cites W2038691484 @default.
• W2981681176 cites W2043222665 @default.
• W2981681176 cites W2054540030 @default.
• W2981681176 cites W2057338076 @default.
• W2981681176 cites W2060004314 @default.
• W2981681176 cites W2074054466 @default.
• W2981681176 cites W2086267154 @default.
• W2981681176 cites W2095872378 @default.
• W2981681176 cites W2100746120 @default.
• W2981681176 cites W2113967301 @default.
• W2981681176 cites W2129509656 @default.
• W2981681176 cites W2131608076 @default.
• W2981681176 cites W2148838644 @default.
• W2981681176 cites W2171177074 @default.
• W2981681176 cites W2312064778 @default.
• W2981681176 cites W2536704990 @default.
• W2981681176 cites W2744608496 @default.
• W2981681176 cites W2771328536 @default.
• W2981681176 cites W2777889365 @default.
• W2981681176 cites W2792107176 @default.
• W2981681176 cites W2940694611 @default.
• W2981681176 cites W2984194970 @default.
• W2981681176 cites W2985843002 @default.
• W2981681176 cites W2987002164 @default.
• W2981681176 doi "https://doi.org/10.1111/bph.14897" @default.
• W2981681176 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7042118" @default.
• W2981681176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31648370" @default.
• W2981681176 hasPublicationYear "2020" @default.
• W2981681176 type Work @default.
• W2981681176 sameAs 2981681176 @default.
• W2981681176 citedByCount "8" @default.
• W2981681176 countsByYear W29816811762020 @default.
• W2981681176 countsByYear W29816811762021 @default.
• W2981681176 countsByYear W29816811762023 @default.
• W2981681176 crossrefType "journal-article" @default.
• W2981681176 hasAuthorship W2981681176A5011433734 @default.
• W2981681176 hasAuthorship W2981681176A5020442907 @default.
• W2981681176 hasAuthorship W2981681176A5021352966 @default.
• W2981681176 hasAuthorship W2981681176A5027193785 @default.
• W2981681176 hasAuthorship W2981681176A5038849475 @default.
• W2981681176 hasAuthorship W2981681176A5049056803 @default.
• W2981681176 hasAuthorship W2981681176A5051378395 @default.
• W2981681176 hasAuthorship W2981681176A5051881041 @default.
• W2981681176 hasAuthorship W2981681176A5060134825 @default.
• W2981681176 hasAuthorship W2981681176A5074196616 @default.
• W2981681176 hasAuthorship W2981681176A5087231670 @default.
• W2981681176 hasBestOaLocation W29816811761 @default.
• W2981681176 hasConcept C112705442 @default.
• W2981681176 hasConcept C197934379 @default.
• W2981681176 hasConcept C203014093 @default.
• W2981681176 hasConcept C2776090121 @default.
• W2981681176 hasConcept C2776727803 @default.
• W2981681176 hasConcept C2908647359 @default.
• W2981681176 hasConcept C2908738225 @default.
• W2981681176 hasConcept C71924100 @default.
• W2981681176 hasConcept C8891405 @default.
• W2981681176 hasConcept C98274493 @default.
• W2981681176 hasConcept C99454951 @default.
• W2981681176 hasConceptScore W2981681176C112705442 @default.
• W2981681176 hasConceptScore W2981681176C197934379 @default.
• W2981681176 hasConceptScore W2981681176C203014093 @default.
• W2981681176 hasConceptScore W2981681176C2776090121 @default.
• W2981681176 hasConceptScore W2981681176C2776727803 @default.
• W2981681176 hasConceptScore W2981681176C2908647359 @default.
• W2981681176 hasConceptScore W2981681176C2908738225 @default.
• W2981681176 hasConceptScore W2981681176C71924100 @default.
• W2981681176 hasConceptScore W2981681176C8891405 @default.
• W2981681176 hasConceptScore W2981681176C98274493 @default.
• W2981681176 hasConceptScore W2981681176C99454951 @default.
• W2981681176 hasIssue "5" @default.
• W2981681176 hasLocation W29816811761 @default.

• next